Brain research bulletin · 2025
Pre-iTBS alleviates perioperative neurocognitive disorders by inducing long-term neuroprotection against inflammatory injury.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zou Binhua, Chen Tingting, Fan Jianzhong, He Renhong
Аннотация
Perioperative neurocognitive disorders (PND), encompassing cognitive impairments linked to anesthesia and surgery, significantly impact elderly patients and increase postoperative risks. Intermittent theta burst stimulation (iTBS), a non-invasive neuromodulation protocol, has shown cognitive-enhancing potential in clinical studies. However, its utility for preventing PND remains unexplored. This study investigated whether preoperative iTBS mitigates PND in aged rats undergoing exploratory laparotomy. Eighteen-month-old male rats (n = 5/group) received 10 daily iTBS sessions or sham stimulation (only noise without real stimulation) prior to 3-hour isoflurane anesthesia (3 %) and laparotomy. Cognitive function was assessed via the Morris water maze (MWM) pre- and postoperatively. Rats were euthanized at 72 h post-surgery to quantify hippocampal microglial polarization (Iba1⁺/CD86⁺), pro-inflammatory cytokines (Milliplex cytokine assays), and neuronal apoptosis (Nissl staining). iTBS-treated rats exhibited faster anesthesia recovery (17.4 ± 3.6 min vs. 35.2 ± 11.2 min; P = 0.009) and reduced postoperative cognitive decline (MWM escape latency: 39.5 ± 5.0 s vs. 50.0 ± 5.8 s; P = 0.006). These improvements correlated with decreased M1-polarized microglia (39.0 ± 7.0 vs. 58.8 ± 12.2; P = 0.014), lower TNF-α levels (2690.6 ± 542.2 pg/mL vs. 3532.7 ± 623.8 pg/mL; P = 0.035), and reduced hippocampal apoptosis (87.8 ± 8.3 % vs. 69.1 ± 13.8 %; P = 0.006). Pre-iTBS has potential therapeutic efficacy in perioperative neurocognitive disorders by reducing M1-type pro-inflammatory factors and enhancing neuronal activity and resistance to anesthesia and surgery-induced damage.